Wells Fargo lowered the firm’s price target on Adaptimmune (ADAP) to $1.50 from $2 and keeps an Equal Weight rating on the shares. Following Q4 results, the firm notes that U.S. Tecelra launch is actually progressing quite rapidly based on penetration rate. However, absolute patient number may be small due to the size of the indication, which requires additional time to reach breakeven, Wells says.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue